ISRG
INTUITIVE SURGICAL INC
- Latest sale
- $38k
- Nov 20 · Routine
- Form 4 sales
- 721
- On record
- Form 144 notices
- 30
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineAug 11 2026
Sold 10,000 shares at $400.00 ($4M)
Guthart Gary S, Director
10b5-1 planSold 0.8% of holdings ($502M position)1.2M shares left0.4x usual sizeFiling
- 2 Form 4 saleRoutineAug 19 +8 days
Sold 231 shares at $392.98 ($91k)
Brosius Mark, EVP & Chief Mfg and Supply Cha
10b5-1 planSold 18.2% of holdings ($498k position)1,035 shares left0.5x usual sizeFiling
- 3 Form 4 saleRoutineAug 21 +2 days
Sold 154 shares at $385.97 ($59k)
Brosius Mark, EVP & Chief Mfg and Supply Cha
10b5-1 planSold 14.9% of holdings ($399k position)881 shares left0.4x usual sizeFiling
- 4 Form 4 saleRoutineSep 9 +19 days
Sold 69 shares at $357.55 ($25k)
Brosius Mark, EVP & Chief Mfg and Supply Cha
10b5-1 planSold 7.8% of holdings ($315k position)812 shares left0.2x usual sizeFiling
- 5 Form 4 saleRoutineSep 11 +2 days
Sold 48 shares at $357.10 ($17k)
Brosius Mark, EVP & Chief Mfg and Supply Cha
10b5-1 planSold 5.9% of holdings ($290k position)764 shares left0.2x usual sizeFiling
- 6 Form 4 saleRoutineSep 15 +4 days
Sold 1,089 shares at $374.44 ($408k)
Widman Fredrik, VP Corporate Controller
10b5-1 planSold 51.5% of holdings ($792k position)1,026 shares left1.9x usual sizeFiling
- 7 Form 4 saleRoutineNov 18 +64 days
Sold 138 shares at $437.45 ($60k)
Brosius Mark, EVP & Chief Mfg and Supply Cha
10b5-1 planSold 30.2% of holdings ($200k position)319 shares left0.9x usual sizeFiling
- 8 Form 4 saleRoutineNov 20 +2 days
Sold 92 shares at $414.10 ($38k)
Brosius Mark, EVP & Chief Mfg and Supply Cha
10b5-1 planSold 28.8% of holdings ($132k position)227 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (newest 400 of 751)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 20, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 92 | $38k | 28.8% | Routine | SEC |
| Nov 18, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 138 | $60k | 30.2% | Routine | SEC |
| Sep 15, 2026 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 1,089 | $408k | 51.5% | Routine | SEC |
| Sep 11, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 48 | $17k | 5.9% | Routine | SEC |
| Sep 9, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 69 | $25k | 7.8% | Routine | SEC |
| Aug 21, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 154 | $59k | 14.9% | Routine | SEC |
| Aug 19, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 231 | $91k | 18.2% | Routine | SEC |
| Aug 11, 2026 | Guthart Gary S | Director | Form 4 sale | 10,000 | $4M | 0.8% | Routine | SEC |
| Aug 11, 2026 | Ladd Amy L | Director | Form 4 sale | 472 | $180k | 72.5% | Routine | SEC |
| Aug 10, 2026 | Loeb Gary | EVP & Chief Legal and Complian | Form 4 sale | 400 | $152k | 7.0% | Routine | SEC |
| Jul 31, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 56 | $20k | 4.2% | Routine | SEC |
| Jul 29, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 84 | $30k | 6.0% | Routine | SEC |
| Jun 12, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 48 | $20k | 3.3% | Routine | SEC |
| Jun 10, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 69 | $29k | 4.5% | Routine | SEC |
| Jun 10, 2026 | Loeb Gary | EVP & Chief Legal and Complian | Form 4 sale | 400 | $170k | 6.5% | Routine | SEC |
| Jun 1, 2026 | Jeddi Iman | SVP & GM da Vinci Platforms & | Form 4 sale | 5,625 | $2.4M | 46.5% | Routine | SEC |
| May 22, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 36 | $16k | 2.3% | Routine | SEC |
| May 20, 2026 | Brosius Mark | EVP & Chief Mfg and Supply Cha | Form 4 sale | 54 | $23k | 3.3% | Routine | SEC |
| May 11, 2026 | Loeb Gary | EVP & Chief Legal and Complian | Form 4 sale | 400 | $179k | 6.1% | Routine | SEC |
| Apr 29, 2026 | Ladd Amy L | Director | Form 4 sale | 619 | $292k | 83.8% | Routine | SEC |
| Mar 10, 2026 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 105 | $52k | 100.0% | Routine | SEC |
| Mar 9, 2026 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 1,293 | $630k | 44.5% | Routine | SEC |
| Mar 5, 2026 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 3,658 | $1.8M | 55.7% | Unusual | SEC |
| Mar 3, 2026 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 367 | $182k | 26.3% | Routine | SEC |
| Mar 3, 2026 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 4,853 | $2.4M | 92.2% | Routine | SEC |
| Feb 27, 2026 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 2,345 | $1.2M | 85.1% | Routine | SEC |
| Feb 27, 2026 | Wadors Patricia L | SVP Chief Human Resources Offi | Form 4 sale | 220 | $110k | 100.0% | Routine | SEC |
| Feb 11, 2026 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 133 | $66k | 16.8% | Routine | SEC |
| Feb 11, 2026 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 526 | $260k | 56.3% | Routine | SEC |
| Jan 29, 2026 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 126 | $66k | 100.0% | Routine | SEC |
| Jan 27, 2026 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 230 | $123k | 100.0% | Routine | SEC |
| Jan 27, 2026 | Guthart Gary S | Director | Form 4 sale | 27,300 | $14.5M | 88.1% | Routine | SEC |
| Dec 15, 2025 | Brosius Mark | Officer | Form 4 sale | 464 | $254k | 78.0% | Routine | SEC |
| Dec 15, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 4,964 | $2.7M | 91.8% | Unusual | SEC |
| Dec 10, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 104 | $58k | 100.0% | Routine | SEC |
| Dec 1, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 125 | $71k | 100.0% | Routine | SEC |
| Dec 1, 2025 | Guthart Gary S | Executive Chair of the Board o | Form 4 sale | 22,806 | $13M | 89.4% | Routine | SEC |
| Nov 12, 2025 | Charlton Henry L | EVP & Chief Commercial and Mkt | Form 4 sale | 13,731 | $8M | 81.8% | Routine | SEC |
| Nov 12, 2025 | Barratt Craig H | Director | Form 4 sale | 750 | $435k | 100.0% | Routine | SEC |
| Nov 10, 2025 | Miller Brian Edward | EVP & Chief Digital Officer | Form 4 sale | 3,500 | $2M | 37.8% | Routine | SEC |
| Nov 10, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 105 | $59k | 100.0% | Routine | SEC |
| Nov 5, 2025 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 2,067 | $1.1M | 81.4% | Routine | SEC |
| Oct 29, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 7,687 | $4.2M | 100.0% | Routine | SEC |
| Oct 24, 2025 | Rosa David J. | Chief Executive Officer (CEO) | Form 4 sale | 24,500 | $13.4M | 9.5% | Routine | SEC |
| Oct 24, 2025 | Guthart Gary S | Executive Chair of the Board o | Form 4 sale | 31,600 | $17.3M | 53.9% | Routine | SEC |
| Oct 24, 2025 | Barratt Craig H | Director | Form 4 sale | 2,193 | $1.2M | 100.0% | Routine | SEC |
| Sep 4, 2025 | Ladd Amy L | Director | Form 4 sale | 671 | $306k | 47.6% | Routine | SEC |
| Aug 29, 2025 | Guthart Gary S | Executive Chair of the Board o | Form 4 sale | 29,360 | $13.9M | 59.7% | Routine | SEC |
| Jul 28, 2025 | Guthart Gary S | Executive Chair of the Board o | Form 4 sale | 10,693 | $5.3M | 44.8% | Routine | SEC |
| Jul 25, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 4,500 | $2.2M | 92.7% | Routine | SEC |
| Jun 6, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 431 | $242k | 32.2% | Routine | SEC |
| Jun 4, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 645 | $355k | 32.5% | Routine | SEC |
| May 16, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 42 | $24k | 2.1% | Routine | SEC |
| May 14, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 66 | $37k | 3.2% | Routine | SEC |
| May 2, 2025 | Samath Jamie | Officer | Form 4 sale | 915 | $483k | 11.3% | Unusual | SEC |
| May 1, 2025 | Nachtsheim Jami K | Director | Form 4 sale | 2,400 | $1.2M | 27.4% | Routine | SEC |
| Apr 30, 2025 | Ladd Amy L | Director | Form 4 sale | 8,776 | $4.4M | 86.2% | Unusual | SEC |
| Apr 29, 2025 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 990 | $509k | 15.9% | Routine | SEC |
| Apr 25, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 4,000 | $2.1M | 91.9% | Routine | SEC |
| Apr 25, 2025 | Loeb Gary | EVP & Chief Legal and Complian | Form 4 sale | 1,700 | $872k | 43.1% | Routine | SEC |
| Mar 13, 2025 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 11,545 | $5.8M | 68.8% | Unusual | SEC |
| Mar 12, 2025 | Miller Brian Edward | EVP & Chief Digital Officer | Form 4 sale | 12,900 | $6.4M | 69.1% | Routine | SEC |
| Mar 7, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 489 | $261k | 19.0% | Routine | SEC |
| Mar 6, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 1,476 | $825k | 36.4% | Unusual | SEC |
| Mar 5, 2025 | Rosa David J. | President | Form 4 sale | 16,509 | $9.2M | 6.6% | Routine | SEC |
| Mar 3, 2025 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 492 | $282k | 10.8% | Routine | SEC |
| Mar 3, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 3,031 | $1.7M | 89.6% | Routine | SEC |
| Mar 3, 2025 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 810 | $465k | 63.1% | Routine | SEC |
| Feb 28, 2025 | Samath Jamie | EVP & CFO & Enterprise Technol | Form 4 sale | 188 | $107k | 2.6% | Routine | SEC |
| Feb 27, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 2,401 | $1.4M | 87.2% | Routine | SEC |
| Feb 26, 2025 | Samath Jamie | EVP & CFO & Enterprise Technol | Form 4 sale | 108 | $62k | 2.2% | Routine | SEC |
| Feb 12, 2025 | Loeb Gary | EVP & Chief Legal and Complian | Form 4 sale | 2,600 | $1.5M | 45.0% | Routine | SEC |
| Feb 11, 2025 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 408 | $241k | 53.6% | Routine | SEC |
| Feb 10, 2025 | Samath Jamie | EVP & CFO & Enterprise Technol | Form 4 sale | 269 | $159k | 7.6% | Routine | SEC |
| Jan 29, 2025 | Samath Jamie | EVP & CFO & Enterprise Technol | Form 4 sale | 6,982 | $4M | 72.6% | Unusual | SEC |
| Jan 28, 2025 | Johnson Amal M | Director | Form 4 sale | 4,635 | $2.6M | 27.4% | Routine | SEC |
| Jan 28, 2025 | Ladd Amy L | Director | Form 4 sale | 150 | $85k | 18.3% | Routine | SEC |
| Dec 10, 2024 | Samath Jamie | CFO and Head of Business Techn | Form 4 sale | 270 | $146k | 3.0% | Routine | SEC |
| Dec 10, 2024 | Samath Jamie | Officer | Form 144 notice | 270 | $146k | Notice | SEC | |
| Nov 29, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 376 | $203k | 6.4% | Routine | SEC |
| Nov 29, 2024 | Samath Jamie | CFO and Head of Business Techn | Form 4 sale | 188 | $101k | 2.1% | Routine | SEC |
| Nov 29, 2024 | Samath Jamie | Officer | Form 144 notice | 188 | $101k | Notice | SEC | |
| Nov 29, 2024 | DeSantis Robert | Officer | Form 144 notice | 376 | $203k | Notice | SEC | |
| Nov 26, 2024 | Samath Jamie | CFO and Head of Business Techn | Form 4 sale | 108 | $59k | 1.2% | Routine | SEC |
| Nov 26, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 396 | $215k | 6.7% | Routine | SEC |
| Nov 26, 2024 | Samath Jamie | Officer | Form 144 notice | 108 | $59k | Notice | SEC | |
| Nov 26, 2024 | DeSantis Robert | Officer | Form 144 notice | 396 | $215k | Notice | SEC | |
| Nov 12, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 13,466 | $7.2M | 97.8% | Unusual | SEC |
| Nov 11, 2024 | Samath Jamie | Officer | Form 4 sale | 23,172 | $12.2M | 72.6% | Routine | SEC |
| Nov 11, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 239 | $129k | 4.2% | Routine | SEC |
| Oct 30, 2024 | Guthart Gary S | CEO | Form 4 sale | 25,591 | $13.1M | 51.4% | Routine | SEC |
| Oct 29, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 1,784 | $915k | 24.5% | Routine | SEC |
| Oct 28, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 44 | $23k | 19.2% | Routine | SEC |
| Oct 24, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 2,172 | $1.1M | 90.5% | Unusual | SEC |
| Oct 22, 2024 | Miller Brian Edward | EVP & Chief Digital Officer | Form 4 sale | 2,553 | $1.3M | 26.5% | Routine | SEC |
| Sep 13, 2024 | Ladd Amy L | Director | Form 4 sale | 450 | $221k | 35.4% | Routine | SEC |
| Sep 12, 2024 | Brosius Mark | Officer | Form 4 sale | 2,115 | $1M | 87.8% | Unusual | SEC |
| Sep 10, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 238 | $114k | 4.1% | Routine | SEC |
| Sep 9, 2024 | Loeb Gary | General Counsel | Form 4 sale | 300 | $143k | 15.8% | Routine | SEC |
| Aug 29, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 376 | $181k | 6.4% | Routine | SEC |
| Aug 26, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 396 | $193k | 6.7% | Routine | SEC |
| Aug 23, 2024 | Charlton Henry L | SVP & Chief Commercial and Mkt | Form 4 sale | 40,243 | $19.6M | 93.1% | Routine | SEC |
| Aug 12, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 240 | $112k | 4.2% | Routine | SEC |
| Aug 1, 2024 | Johnson Amal M | Director | Form 4 sale | 2,943 | $1.3M | 19.3% | Routine | SEC |
| Jul 30, 2024 | Guthart Gary S | CEO | Form 4 sale | 30,828 | $13.7M | 64.2% | Routine | SEC |
| Jul 29, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 1,789 | $788k | 24.5% | Routine | SEC |
| Jul 23, 2024 | Barratt Craig H | Director | Form 4 sale | 1,400 | $641k | 100.0% | Routine | SEC |
| Jul 23, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 2,818 | $1.3M | 90.4% | Routine | SEC |
| Jun 12, 2024 | Barratt Craig H | Director | Form 4 sale | 1,400 | $589k | 100.0% | Routine | SEC |
| Jun 10, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 239 | $100k | 4.2% | Routine | SEC |
| Jun 5, 2024 | Barratt Craig H | Director | Form 4 sale | 1,400 | $575k | 100.0% | Routine | SEC |
| Jun 3, 2024 | Barratt Craig H | Director | Form 4 sale | 2,496 | $1M | 100.0% | Routine | SEC |
| May 29, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 772 | $311k | 12.3% | Routine | SEC |
| May 17, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 238 | $95k | 44.7% | Routine | SEC |
| May 16, 2024 | Miller Brian Edward | EVP & Chief Digital Officer | Form 4 sale | 2,553 | $1M | 21.0% | Routine | SEC |
| May 15, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 525 | $203k | 49.6% | Unusual | SEC |
| May 13, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 523 | $203k | 8.7% | Routine | SEC |
| May 3, 2024 | Rubash Mark J | Director | Form 4 sale | 1,709 | $649k | 9.6% | Routine | SEC |
| Apr 29, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 1,874 | $695k | 25.4% | Routine | SEC |
| Apr 23, 2024 | Levy Alan J | Director | Form 4 sale | 2,000 | $741k | 7.3% | Routine | SEC |
| Apr 23, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 5,318 | $2M | 94.7% | Routine | SEC |
| Mar 15, 2024 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 5,041 | $2M | 97.9% | Unusual | SEC |
| Mar 11, 2024 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 20,625 | $8.1M | 78.9% | Unusual | SEC |
| Mar 11, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 392 | $153k | 27.0% | Unusual | SEC |
| Mar 7, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 588 | $231k | 28.9% | Unusual | SEC |
| Mar 1, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 1,605 | $615k | 84.3% | Routine | SEC |
| Feb 28, 2024 | Mohr Marshall | Executive VP Global Business S | Form 4 sale | 108,790 | $41.9M | 69.4% | Routine | SEC |
| Feb 27, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 843 | $326k | 73.9% | Unusual | SEC |
| Feb 16, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 92 | $35k | 11.5% | Routine | SEC |
| Feb 13, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 60 | $23k | 7.0% | Routine | SEC |
| Feb 12, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 481 | $186k | 61.7% | Routine | SEC |
| Feb 7, 2024 | Rosa David J. | President | Form 4 sale | 80,710 | $31.4M | 27.4% | Routine | SEC |
| Feb 1, 2024 | Brosius Mark | SVP & Chief Mfg and Supply Cha | Form 4 sale | 39 | $15k | 8.0% | Routine | SEC |
| Jan 29, 2024 | Guthart Gary S | CEO | Form 4 sale | 29,285 | $11M | 75.7% | Routine | SEC |
| Jan 26, 2024 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 4,318 | $1.6M | 95.8% | Routine | SEC |
| Jan 26, 2024 | Levy Alan J | Director | Form 4 sale | 2,000 | $740k | 7.3% | Routine | SEC |
| Jan 26, 2024 | Johnson Amal M | Director | Form 4 sale | 6,696 | $2.5M | 36.4% | Routine | SEC |
| Nov 16, 2023 | Johnson Amal M | Director | Form 4 sale | 9,567 | $2.9M | 45.0% | Routine | SEC |
| Nov 16, 2023 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 8,819 | $2.6M | 97.9% | Routine | SEC |
| Nov 16, 2023 | Curet Myriam | Officer | Form 144 notice | 8,819 | $2.6M | Notice | SEC | |
| Nov 16, 2023 | Johnson Amal M | Director | Form 144 notice | 9,567 | $2.9M | Notice | SEC | |
| Nov 14, 2023 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 867 | $251k | 10.7% | No plan | SEC |
| Nov 14, 2023 | Levy Alan J | Director | Form 4 sale | 2,000 | $580k | 7.3% | Routine | SEC |
| Nov 14, 2023 | DeSantis Robert | Officer | Form 144 notice | 867 | $251k | Notice | SEC | |
| Nov 14, 2023 | Levy Alan J | Director | Form 144 notice | 2,000 | $580k | Notice | SEC | |
| Oct 26, 2023 | Guthart Gary S | Officer, Director | Form 144 notice | 27,385 | $7.1M | Notice | SEC | |
| Oct 26, 2023 | Guthart Gary S | CEO | Form 4 sale | 32,345 | $8.5M | 57.9% | Routine | SEC |
| Oct 24, 2023 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 1,110 | $304k | 13.3% | No plan | SEC |
| Oct 24, 2023 | DeSantis Robert | Officer | Form 144 notice | 1,110 | $304k | Notice | SEC | |
| Oct 24, 2023 | Guthart Gary S | Officer, Director | Form 144 notice | 4,960 | $1.4M | Notice | SEC | |
| Sep 14, 2023 | Ladd Amy L | Director | Form 4 sale | 500 | $153k | 41.6% | Routine | SEC |
| Sep 14, 2023 | Ladd Amy L | Director | Form 144 notice | 500 | $153k | Notice | SEC | |
| Aug 29, 2023 | DiMartino Michele | Officer | Form 144 notice | 1,315 | $408k | Notice | SEC | |
| Aug 7, 2023 | Levy Alan J | Director | Form 4 sale | 2,000 | $620k | 7.3% | Routine | SEC |
| Aug 7, 2023 | Levy Alan J | Director | Form 144 notice | 2,000 | $620k | Notice | SEC | |
| Jul 31, 2023 | Guthart Gary S | CEO | Form 4 sale | 55,274 | $18.1M | 76.3% | Unusual | SEC |
| Jul 31, 2023 | Guthart Gary S | Officer, Director | Form 144 notice | 4,960 | $1.6M | Notice | SEC | |
| Jul 28, 2023 | Guthart Gary S | Officer, Director | Form 144 notice | 50,314 | $16.4M | Notice | SEC | |
| Jul 25, 2023 | DeSantis Robert | EVP & Chief Strategy & Corp Op | Form 4 sale | 2,535 | $819k | 25.9% | Unusual | SEC |
| Jul 25, 2023 | DeSantis Robert | Officer | Form 144 notice | 2,535 | $819k | Notice | SEC | |
| Jun 14, 2023 | Mohr Marshall | Executive VP Global Business S | Form 4 sale | 11,250 | $3.7M | 31.8% | Unusual | SEC |
| Jun 14, 2023 | Barratt Craig H | Director | Form 4 sale | 1,567 | $506k | 100.0% | Unusual | SEC |
| Jun 14, 2023 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 2,443 | $794k | 25.2% | Unusual | SEC |
| Jun 14, 2023 | Mohr Marshall | Officer | Form 144 notice | 11,250 | $3.7M | Notice | SEC | |
| Jun 14, 2023 | DeSantis Robert | Officer | Form 144 notice | 2,443 | $794k | Notice | SEC | |
| Jun 14, 2023 | Barratt Craig H | Director | Form 144 notice | 1,567 | $506k | Notice | SEC | |
| May 1, 2023 | Barratt Craig H | Director | Form 4 sale | 2,000 | $612k | 100.0% | Unusual | SEC |
| May 1, 2023 | Barratt Craig H | Director | Form 144 notice | 2,000 | $612k | Notice | SEC | |
| Apr 28, 2023 | Rubash Mark J | Director | Form 4 sale | 7,323 | $2.2M | 32.1% | Unusual | SEC |
| Apr 28, 2023 | Rubash Mark J | Director | Form 144 notice | 7,323 | $2.2M | Notice | SEC | |
| Apr 24, 2023 | Rosa David J. | Officer | Form 144 notice | 40,764 | $12.2M | Notice | SEC | |
| Apr 24, 2023 | Rosa David J. | EVP Chief Strategy & Growth Of | Form 4 sale | 81,564 | $24.4M | 34.4% | Unusual | SEC |
| Apr 21, 2023 | Rubash Mark J | Director | Form 4 sale | 1,683 | $501k | 10.1% | No plan | SEC |
| Apr 21, 2023 | Rubash Mark J | Director | Form 4 sale | 8,135 | $2.4M | 35.2% | Unusual | SEC |
| Apr 21, 2023 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 630 | $188k | 22.0% | No plan | SEC |
| Apr 21, 2023 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 8,623 | $2.6M | 55.0% | Unusual | SEC |
| Apr 21, 2023 | Barratt Craig H | Director | Form 4 sale | 6,000 | $1.8M | 100.0% | Unusual | SEC |
| Apr 21, 2023 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 9,623 | $2.9M | 96.7% | Unusual | SEC |
| Apr 21, 2023 | Rosa David J. | Officer | Form 144 notice | 40,800 | $12.2M | Notice | SEC | |
| Apr 21, 2023 | Barratt Craig H | Director | Form 144 notice | 6,000 | $1.8M | Notice | SEC | |
| Apr 21, 2023 | DeSantis Robert | Officer | Form 144 notice | 8,623 | $2.6M | Notice | SEC | |
| Apr 21, 2023 | Curet Myriam | Officer | Form 144 notice | 9,623 | $2.9M | Notice | SEC | |
| Apr 21, 2023 | Rubash Mark J | Director | Form 144 notice | 9,818 | $2.9M | Notice | SEC | |
| Apr 21, 2023 | Widman Fredrik | Officer | Form 144 notice | 630 | $188k | Notice | SEC | |
| Mar 1, 2023 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 1,253 | $286k | 39.1% | Unusual | SEC |
| Feb 16, 2023 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 116 | $28k | 6.7% | Plan not stated | SEC |
| Feb 16, 2023 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 1,124 | $271k | 77.5% | Unusual | SEC |
| Feb 16, 2023 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 1,971 | $475k | 23.6% | Plan not stated | SEC |
| Feb 13, 2023 | Mohr Marshall | Executive VP Global Business S | Form 4 sale | 33,249 | $8.2M | 61.6% | Unusual | SEC |
| Feb 13, 2023 | Widman Fredrik | VP Corporate Controller | Form 4 sale | 1,307 | $322k | 46.7% | Unusual | SEC |
| Feb 6, 2023 | Rosa David J. | EVP Chief Strategy & Growth Of | Form 4 sale | 45,025 | $11.3M | 26.4% | Unusual | SEC |
| Jan 27, 2023 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 1,629 | $407k | 19.4% | Plan not stated | SEC |
| Nov 8, 2022 | Johnson Amal M | Director | Form 4 sale | 6,375 | $1.5M | 36.2% | Unusual | SEC |
| Nov 1, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 8,000 | $2M | 97.4% | Unusual | SEC |
| Oct 21, 2022 | Guthart Gary S | President & CEO | Form 4 sale | 44,203 | $9.3M | 65.5% | Unusual | SEC |
| Oct 21, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 8,000 | $1.7M | 97.4% | Unusual | SEC |
| Sep 8, 2022 | Johnson Amal M | Director | Form 4 sale | 6,375 | $1.3M | 36.2% | Unusual | SEC |
| Aug 15, 2022 | Name not stated | Director | Form 4 sale | 600 | $142k | 45.5% | Unusual | SEC |
| Aug 3, 2022 | Johnson Amal M | Director | Form 4 sale | 6,375 | $1.5M | 36.2% | Unusual | SEC |
| Jul 27, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 9,000 | $2M | 97.6% | Unusual | SEC |
| Jul 26, 2022 | Guthart Gary S | President & CEO | Form 4 sale | 79,412 | $17.2M | 59.3% | Unusual | SEC |
| Apr 26, 2022 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 1,611 | $408k | 20.2% | Plan not stated | SEC |
| Apr 26, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 6,000 | $1.5M | 94.3% | Unusual | SEC |
| Mar 1, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 2,000 | $580k | 84.7% | Unusual | SEC |
| Feb 16, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 2,478 | $716k | 87.3% | Unusual | SEC |
| Jan 25, 2022 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 6,000 | $1.6M | 95.5% | Unusual | SEC |
| Jan 25, 2022 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 1,410 | $369k | 56.4% | Unusual | SEC |
| Nov 24, 2021 | Johnson Amal M | Director | Form 4 sale | 7,500 | $2.5M | 41.3% | Unusual | SEC |
| Oct 25, 2021 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 20,475 | $6.9M | 100.0% | Unusual | SEC |
| Oct 22, 2021 | Samath Jamie | SVP of Finance | Form 4 sale | 1,503 | $511k | 66.4% | Unusual | SEC |
| Oct 22, 2021 | Levy Alan J | Director | Form 4 sale | 7,500 | $2.5M | 23.6% | Unusual | SEC |
| Oct 22, 2021 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 6,000 | $2M | 95.5% | Unusual | SEC |
| Oct 22, 2021 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 1,014 | $345k | 48.1% | Unusual | SEC |
| Sep 9, 2021 | Rubash Mark J | Director | Form 4 sale | 1,196 | $1.3M | 19.9% | Plan not stated | SEC |
| Sep 9, 2021 | Curet Myriam | EVP & Chief Medical Officer | Form 4 sale | 4,250 | $4.6M | 97.8% | Unusual | SEC |
| Aug 26, 2021 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 397 | $416k | 52.2% | Unusual | SEC |
| Aug 11, 2021 | Johnson Amal M | Director | Form 4 sale | 2,500 | $2.5M | 40.2% | Unusual | SEC |
| Aug 6, 2021 | Rosa David J. | EVP & Chief Business Officer | Form 4 sale | 16,211 | $16.4M | 30.2% | Unusual | SEC |
| Aug 3, 2021 | Leonard Keith R | Director | Form 4 sale | 996 | $996k | 54.0% | Unusual | SEC |
| Jul 26, 2021 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 6,825 | $6.6M | 100.0% | Unusual | SEC |
| Jul 23, 2021 | DeSantis Robert | EVP & Chief Product Officer | Form 4 sale | 4,004 | $3.9M | 91.7% | Unusual | SEC |
| Jul 23, 2021 | Samath Jamie | SVP of Finance | Form 4 sale | 503 | $489k | 66.5% | Unusual | SEC |
| Jul 23, 2021 | Barratt Craig H | Director | Form 4 sale | 1,275 | $1.2M | 100.0% | Unusual | SEC |
| Jul 23, 2021 | Ladd Amy L | Director | Form 4 sale | 128 | $124k | 33.4% | Unusual | SEC |
| Jul 23, 2021 | Levy Alan J | Director | Form 4 sale | 2,500 | $2.4M | 23.6% | Plan not stated | SEC |
| Jun 15, 2021 | Rosa David J. | EVP and Chief Business Officer | Form 4 sale | 17,038 | $14.9M | 34.2% | Unusual | SEC |
| May 12, 2021 | Johnson Amal M | Director | Form 4 sale | 2,500 | $2M | 40.2% | Unusual | SEC |
| May 4, 2021 | Guthart Gary S | President & CEO | Form 4 sale | 10,617 | $9M | 75.8% | Unusual | SEC |
| Apr 26, 2021 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 21,963 | $19M | 72.3% | Unusual | SEC |
| Apr 26, 2021 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 875 | $758k | 90.3% | Unusual | SEC |
| Apr 23, 2021 | Samath Jamie | SVP of Finance | Form 4 sale | 793 | $673k | 75.8% | Unusual | SEC |
| Apr 23, 2021 | Levy Alan J | Director | Form 4 sale | 2,500 | $2.1M | 23.6% | Plan not stated | SEC |
| Apr 23, 2021 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 750 | $636k | 13.4% | Plan not stated | SEC |
| Apr 23, 2021 | Barratt Craig H | Director | Form 4 sale | 5,100 | $4.4M | 100.0% | Unusual | SEC |
| Mar 2, 2021 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 379 | $288k | 80.1% | Unusual | SEC |
| Mar 2, 2021 | Samath Jamie | SVP of Finance | Form 4 sale | 215 | $163k | 45.9% | Unusual | SEC |
| Feb 17, 2021 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 4,423 | $2.8M | 97.9% | Unusual | SEC |
| Feb 17, 2021 | DeSantis Robert | Executive VP & GM IA&E | Form 4 sale | 2,958 | $2.3M | 53.8% | Unusual | SEC |
| Feb 17, 2021 | Samath Jamie | SVP of Finance | Form 4 sale | 655 | $512k | 72.1% | Unusual | SEC |
| Feb 11, 2021 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 12,487 | $10M | 59.3% | Unusual | SEC |
| Feb 2, 2021 | Guthart Gary S | President & CEO | Form 4 sale | 11,020 | $8.4M | 78.7% | Unusual | SEC |
| Jan 29, 2021 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 9,375 | $7M | 99.5% | Unusual | SEC |
| Jan 26, 2021 | Samath Jamie | SVP of Finance | Form 4 sale | 521 | $393k | 71.6% | Unusual | SEC |
| Jan 26, 2021 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 1,652 | $1.2M | 31.1% | Unusual | SEC |
| Jan 26, 2021 | Levy Alan J | Director | Form 4 sale | 2,500 | $1.9M | 24.2% | Plan not stated | SEC |
| Dec 9, 2020 | Guthart Gary S | President & CEO | Form 4 sale | 16,914 | $12.9M | 6.3% | Plan not stated | SEC |
| Dec 7, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 407 | $317k | 66.3% | Unusual | SEC |
| Oct 26, 2020 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 6,000 | $4.3M | 29.0% | Unusual | SEC |
| Oct 20, 2020 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 875 | $644k | 22.7% | Plan not stated | SEC |
| Oct 20, 2020 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 1,250 | $920k | 23.5% | Plan not stated | SEC |
| Oct 20, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 754 | $555k | 78.5% | Unusual | SEC |
| Oct 20, 2020 | Levy Alan J | Director | Form 4 sale | 1,800 | $1.3M | 18.7% | Plan not stated | SEC |
| Sep 10, 2020 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 1,514 | $1.1M | 27.1% | Unusual | SEC |
| Aug 31, 2020 | Rubash Mark J | Director | Form 4 sale | 1,000 | $724k | 18.0% | Plan not stated | SEC |
| Aug 5, 2020 | Rosa David J. | EVP and Chief Business Officer | Form 4 sale | 16,840 | $11.7M | 38.9% | Unusual | SEC |
| Jul 27, 2020 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 7,500 | $5.1M | 33.8% | Unusual | SEC |
| Jul 24, 2020 | DeSantis Robert | Executive VP & GM IA&E | Form 4 sale | 1,798 | $1.2M | 34.9% | Unusual | SEC |
| Jul 24, 2020 | Ladd Amy L | Director | Form 4 sale | 55 | $37k | 30.1% | Unusual | SEC |
| Jul 24, 2020 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 887 | $590k | 22.4% | Plan not stated | SEC |
| Jul 21, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 752 | $499k | 78.4% | Unusual | SEC |
| Jul 21, 2020 | Levy Alan J | Director | Form 4 sale | 1,800 | $1.2M | 18.7% | Plan not stated | SEC |
| Jul 21, 2020 | Nachtsheim Jami K | Director | Form 4 sale | 20 | $13k | 1.8% | Plan not stated | SEC |
| Jun 15, 2020 | Rosa David J. | EVP and Chief Business Officer | Form 4 sale | 17,950 | $9.9M | 48.2% | Unusual | SEC |
| Jun 5, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 289 | $173k | 58.3% | Unusual | SEC |
| May 26, 2020 | Levy Alan J | Director | Form 4 sale | 1,950 | $1.1M | 19.9% | Plan not stated | SEC |
| May 20, 2020 | Johnson Amal M | Director | Form 4 sale | 3,000 | $1.6M | 24.1% | Plan not stated | SEC |
| May 20, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 286 | $157k | 58.0% | Unusual | SEC |
| May 5, 2020 | Guthart Gary S | President & CEO | Form 4 sale | 23,430 | $12M | 5.6% | Plan not stated | SEC |
| Apr 29, 2020 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 7,500 | $3.9M | 33.8% | Unusual | SEC |
| Apr 22, 2020 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 3,000 | $1.5M | 49.5% | Unusual | SEC |
| Apr 21, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 248 | $126k | 54.5% | Unusual | SEC |
| Feb 19, 2020 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 2,058 | $1.2M | 40.2% | Unusual | SEC |
| Feb 19, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 1,118 | $666k | 84.4% | Unusual | SEC |
| Feb 14, 2020 | Smith Lonnie M | Director | Form 4 sale | 28,200 | $16.9M | 9.1% | Unusual | SEC |
| Feb 13, 2020 | Smith Lonnie M | Director | Form 4 sale | 8,027 | $4.8M | 2.6% | Unusual | SEC |
| Feb 13, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 1,492 | $895k | 87.8% | Unusual | SEC |
| Feb 13, 2020 | Leonard Keith R | Director | Form 4 sale | 1,545 | $927k | 82.3% | Unusual | SEC |
| Feb 5, 2020 | Guthart Gary S | President & CEO | Form 4 sale | 22,233 | $12.8M | 5.5% | Plan not stated | SEC |
| Feb 5, 2020 | Johnson Amal M | Director | Form 4 sale | 4,250 | $2.5M | 31.6% | Unusual | SEC |
| Feb 3, 2020 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 7,500 | $4.2M | 37.6% | Unusual | SEC |
| Feb 3, 2020 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 400 | $225k | 12.4% | Plan not stated | SEC |
| Feb 3, 2020 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 3,000 | $1.7M | 49.5% | Unusual | SEC |
| Jan 29, 2020 | Levy Alan J | Director | Form 4 sale | 1,950 | $1.1M | 20.5% | Plan not stated | SEC |
| Jan 28, 2020 | Samath Jamie | SVP of Finance | Form 4 sale | 451 | $257k | 73.9% | Unusual | SEC |
| Dec 6, 2019 | Samath Jamie | SVP of Finance | Form 4 sale | 225 | $132k | 58.6% | Unusual | SEC |
| Dec 5, 2019 | Guthart Gary S | President & CEO | Form 4 sale | 22,377 | $13M | 5.6% | Plan not stated | SEC |
| Dec 2, 2019 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 12,368 | $7.3M | 74.9% | Unusual | SEC |
| Nov 19, 2019 | Rubash Mark J | Director | Form 4 sale | 1,000 | $580k | 18.9% | Plan not stated | SEC |
| Nov 8, 2019 | Smith Lonnie M | Director | Form 4 sale | 205 | $114k | 0.1% | Plan not stated | SEC |
| Oct 28, 2019 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 7,500 | $4.1M | 37.2% | Unusual | SEC |
| Oct 22, 2019 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 3,000 | $1.7M | 49.2% | Unusual | SEC |
| Oct 22, 2019 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 2,042 | $1.1M | 39.1% | Unusual | SEC |
| Oct 22, 2019 | Samath Jamie | SVP of Finance | Form 4 sale | 1,021 | $569k | 86.5% | Unusual | SEC |
| Sep 3, 2019 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 1,171 | $592k | 17.9% | Plan not stated | SEC |
| Aug 20, 2019 | Smith Lonnie M | Director | Form 4 sale | 215 | $106k | 0.1% | Plan not stated | SEC |
| Aug 19, 2019 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 130 | $65k | 45.0% | Unusual | SEC |
| Jul 29, 2019 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 15,000 | $7.9M | 54.3% | Unusual | SEC |
| Jul 24, 2019 | Andersen Reiter Kara | Sr VP General Counsel & CCO | Form 4 sale | 4,120 | $2.2M | 52.6% | Unusual | SEC |
| Jul 23, 2019 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 4,974 | $2.6M | 61.6% | Unusual | SEC |
| Jul 23, 2019 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 259 | $138k | 62.0% | Unusual | SEC |
| Jun 10, 2019 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 1,172 | $587k | 17.9% | Plan not stated | SEC |
| Jun 10, 2019 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 130 | $65k | 45.0% | Unusual | SEC |
| May 16, 2019 | Smith Lonnie M | Director | Form 4 sale | 227 | $112k | 0.1% | Plan not stated | SEC |
| May 6, 2019 | Guthart Gary S | President & CEO | Form 4 sale | 22,636 | $11.4M | 5.9% | Plan not stated | SEC |
| Apr 23, 2019 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 2,200 | $1.1M | 41.5% | Unusual | SEC |
| Apr 23, 2019 | Friedman Michael A | Director | Form 4 sale | 996 | $498k | 17.3% | Plan not stated | SEC |
| Apr 23, 2019 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 260 | $130k | 62.1% | Unusual | SEC |
| Mar 1, 2019 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 2,090 | $1.2M | 28.0% | Unusual | SEC |
| Feb 26, 2019 | Smith Lonnie M | Director | Form 4 sale | 210 | $115k | 0.1% | Plan not stated | SEC |
| Feb 21, 2019 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 2,236 | $1.2M | 96.6% | Unusual | SEC |
| Feb 20, 2019 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 1,410 | $771k | 31.5% | Unusual | SEC |
| Feb 5, 2019 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 7,500 | $3.9M | 44.0% | Unusual | SEC |
| Feb 4, 2019 | Guthart Gary S | President & CEO | Form 4 sale | 28,152 | $14.7M | 7.4% | Plan not stated | SEC |
| Jan 29, 2019 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 458 | $229k | 85.3% | Unusual | SEC |
| Dec 3, 2018 | Guthart Gary S | President & CEO | Form 4 sale | 28,085 | $15.2M | 7.6% | Plan not stated | SEC |
| Dec 3, 2018 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 2,090 | $1.1M | 58.4% | Unusual | SEC |
| Dec 3, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 227 | $123k | 74.2% | Unusual | SEC |
| Nov 7, 2018 | Smith Lonnie M | Director | Form 4 sale | 225 | $122k | 0.1% | Plan not stated | SEC |
| Oct 31, 2018 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 7,500 | $3.9M | 43.3% | Unusual | SEC |
| Oct 23, 2018 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 1,100 | $548k | 36.2% | Unusual | SEC |
| Oct 23, 2018 | Johnson Amal M | Director | Form 4 sale | 1,000 | $500k | 10.1% | Plan not stated | SEC |
| Oct 23, 2018 | Rosa David J. | EVP & Chief Commercial Officer | Form 4 sale | 32,500 | $16.3M | 73.5% | Unusual | SEC |
| Oct 23, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 864 | $431k | 91.6% | Unusual | SEC |
| Sep 7, 2018 | Friedman Michael A | Director | Form 4 sale | 2,070 | $1.1M | 31.9% | Unusual | SEC |
| Sep 4, 2018 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 2,652 | $1.5M | 64.1% | Unusual | SEC |
| Aug 31, 2018 | Rubash Mark J | Director | Form 4 sale | 350 | $196k | 8.1% | Plan not stated | SEC |
| Aug 27, 2018 | Rubash Mark J | Director | Form 4 sale | 150 | $82k | 3.6% | Plan not stated | SEC |
| Aug 6, 2018 | Smith Lonnie M | Director | Form 4 sale | 245 | $128k | 0.1% | Plan not stated | SEC |
| Aug 6, 2018 | Guthart Gary S | President & CEO | Form 4 sale | 35,672 | $18.6M | 9.8% | Plan not stated | SEC |
| Jul 30, 2018 | Mohr Marshall | Executive VP & CFO | Form 4 sale | 8,250 | $4.2M | 45.7% | Unusual | SEC |
| Jul 24, 2018 | Barratt Craig H | Director | Form 4 sale | 2,500 | $1.3M | 100.0% | Unusual | SEC |
| Jul 24, 2018 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 712 | $373k | 26.5% | Unusual | SEC |
| Jul 24, 2018 | Smith Lonnie M | Director | Form 4 sale | 56,000 | $29.3M | 12.9% | Unusual | SEC |
| Jul 24, 2018 | Rosa David J. | EVP & Chief Commercial Officer | Form 4 sale | 20,000 | $10.5M | 64.2% | Unusual | SEC |
| Jul 24, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 862 | $451k | 91.6% | Unusual | SEC |
| Jul 24, 2018 | Johnson Amal M | Director | Form 4 sale | 3,000 | $1.6M | 25.3% | Unusual | SEC |
| Jun 7, 2018 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 6,000 | $2.9M | 37.4% | Unusual | SEC |
| Jun 5, 2018 | Rubash Mark J | Director | Form 4 sale | 1,000 | $490k | 20.1% | Plan not stated | SEC |
| Jun 4, 2018 | Barratt Craig H | Director | Form 4 sale | 2,500 | $1.2M | 100.0% | Unusual | SEC |
| Jun 4, 2018 | Smith Lonnie M | Director | Form 4 sale | 9,333 | $4.5M | 2.0% | Unusual | SEC |
| Jun 1, 2018 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 2,655 | $1.2M | 64.1% | Unusual | SEC |
| Jun 1, 2018 | Rubash Mark J | Director | Form 4 sale | 1,000 | $470k | 20.1% | Plan not stated | SEC |
| May 14, 2018 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 8,078 | $3.8M | 80.4% | Unusual | SEC |
| May 14, 2018 | Smith Lonnie M | Director | Form 4 sale | 265 | $123k | 0.1% | Plan not stated | SEC |
| Apr 30, 2018 | Guthart Gary S | President & CEO | Form 4 sale | 36,642 | $16.4M | 10.8% | Plan not stated | SEC |
| Apr 24, 2018 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 263 | $118k | 11.8% | Plan not stated | SEC |
| Apr 24, 2018 | Mohr Marshall | SVP & CFO | Form 4 sale | 7,500 | $3.4M | 43.3% | Unusual | SEC |
| Apr 23, 2018 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 2,770 | $1.3M | 58.4% | Unusual | SEC |
| Apr 20, 2018 | Friedman Michael A | Director | Form 4 sale | 2,181 | $999k | 38.8% | Unusual | SEC |
| Apr 20, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 1,060 | $485k | 93.1% | Unusual | SEC |
| Apr 20, 2018 | Rosa David J. | EVP & Chief Commercial Officer | Form 4 sale | 54,000 | $24.7M | 82.9% | Unusual | SEC |
| Apr 20, 2018 | Smith Lonnie M | Director | Form 4 sale | 46,667 | $21.3M | 9.0% | Unusual | SEC |
| Mar 9, 2018 | Barratt Craig H | Director | Form 4 sale | 2,500 | $1.1M | 100.0% | Unusual | SEC |
| Mar 6, 2018 | Rubash Mark J | Director | Form 4 sale | 1,000 | $430k | 22.5% | Plan not stated | SEC |
| Mar 5, 2018 | Rubash Mark J | Director | Form 4 sale | 1,000 | $420k | 22.5% | Plan not stated | SEC |
| Mar 1, 2018 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 7,934 | $3.3M | 84.2% | Unusual | SEC |
| Feb 27, 2018 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 24,000 | $10.4M | 70.5% | Unusual | SEC |
| Feb 21, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 775 | $327k | 90.7% | Unusual | SEC |
| Feb 20, 2018 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 6,000 | $2.5M | 37.4% | Unusual | SEC |
| Feb 20, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 861 | $362k | 50.2% | Unusual | SEC |
| Feb 7, 2018 | Guthart Gary S | President & CEO | Form 4 sale | 7,724 | $3.2M | 2.7% | Plan not stated | SEC |
| Feb 5, 2018 | Guthart Gary S | President & CEO | Form 4 sale | 28,525 | $11.8M | 9.2% | Plan not stated | SEC |
| Feb 5, 2018 | Mohr Marshall | SVP & CFO | Form 4 sale | 7,500 | $3.1M | 54.3% | Unusual | SEC |
| Jan 30, 2018 | Myriam Curet | EVP & Chief Medical Officer | Form 4 sale | 262 | $113k | 12.2% | Plan not stated | SEC |
| Jan 30, 2018 | Smith Lonnie M | Director | Form 4 sale | 18,000 | $7.7M | 3.4% | Unusual | SEC |
| Jan 30, 2018 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 964 | $413k | 100.0% | Unusual | SEC |
| Dec 1, 2017 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 959 | $382k | 100.0% | Unusual | SEC |
| Dec 1, 2017 | Brogna Salvatore | EVP & Chief Operating Officer | Form 4 sale | 6,082 | $2.4M | 81.2% | Unusual | SEC |
| Dec 1, 2017 | Rubash Mark J | Director | Form 4 sale | 6,000 | $2.4M | 63.5% | Unusual | SEC |
| Nov 30, 2017 | Johnson Amal M | Director | Form 4 sale | 3,000 | $1.2M | 26.4% | Unusual | SEC |
| Nov 27, 2017 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 3,000 | $1.2M | 30.3% | Unusual | SEC |
| Nov 21, 2017 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 6,000 | $2.4M | 46.6% | Unusual | SEC |
| Nov 10, 2017 | Smith Lonnie M | Director | Form 4 sale | 580 | $224k | 0.2% | Plan not stated | SEC |
| Oct 30, 2017 | Mohr Marshall | SVP & CFO | Form 4 sale | 6,000 | $2.2M | 48.7% | Unusual | SEC |
| Oct 26, 2017 | Barratt Craig H | Director | Form 4 sale | 7,500 | $2.9M | 100.0% | Unusual | SEC |
| Oct 24, 2017 | Rubash Mark J | Director | Form 4 sale | 6,750 | $2.5M | 66.2% | Unusual | SEC |
| Oct 24, 2017 | Smith Lonnie M | Director | Form 4 sale | 18,000 | $6.7M | 3.1% | Unusual | SEC |
| Oct 24, 2017 | Levy Alan J | Director | Form 4 sale | 2,997 | $1.1M | 31.1% | Unusual | SEC |
| Oct 24, 2017 | Barratt Craig H | Director | Form 4 sale | 15,000 | $5.6M | 100.0% | Unusual | SEC |
| Oct 24, 2017 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 1,564 | $581k | 100.0% | Unusual | SEC |
| Oct 24, 2017 | Myriam Curet | SVP & Chief Medical Officer | Form 4 sale | 262 | $98k | 11.4% | Plan not stated | SEC |
| Sep 5, 2017 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 500 | $513k | 17.9% | Plan not stated | SEC |
| Sep 1, 2017 | Brogna Salvatore | EVP - Product Operations | Form 4 sale | 899 | $901k | 65.7% | Unusual | SEC |
| Aug 31, 2017 | Johnson Amal M | Director | Form 4 sale | 1,000 | $996k | 26.4% | Unusual | SEC |
| Aug 31, 2017 | Leonard Keith R | Director | Form 4 sale | 854 | $854k | 100.0% | Unusual | SEC |
| Aug 22, 2017 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 500 | $491k | 17.9% | Plan not stated | SEC |
| Jul 27, 2017 | Guthart Gary S | President & CEO | Form 4 sale | 17,975 | $16.8M | 17.7% | Plan not stated | SEC |
| Jul 25, 2017 | Smith Lonnie M | Director | Form 4 sale | 3,000 | $2.8M | 1.6% | Plan not stated | SEC |
| Jul 25, 2017 | Levy Alan J | Director | Form 4 sale | 999 | $948k | 31.1% | Unusual | SEC |
| Jul 25, 2017 | Myriam Curet | SVP & Chief Medical Officer | Form 4 sale | 1,202 | $1.1M | 63.9% | Unusual | SEC |
| Jul 25, 2017 | Rubash Mark J | Director | Form 4 sale | 2,688 | $2.5M | 70.0% | Unusual | SEC |
| Jul 25, 2017 | Friedman Michael A | Director | Form 4 sale | 1,000 | $946k | 50.6% | Unusual | SEC |
| Jul 25, 2017 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 242 | $230k | 100.0% | Unusual | SEC |
| Jun 12, 2017 | Meltzer Mark J | SVP General Counsel & CCO | Form 4 sale | 3,000 | $2.7M | 56.6% | Unusual | SEC |
| Jun 8, 2017 | Rubash Mark J | Director | Form 4 sale | 3,000 | $2.8M | 72.3% | Unusual | SEC |
| Jun 7, 2017 | Myriam Curet | SVP & Chief Medical Officer | Form 4 sale | 750 | $698k | 52.5% | Unusual | SEC |
| Jun 5, 2017 | Myriam Curet | SVP & Chief Medical Officer | Form 4 sale | 2,644 | $2.4M | 79.6% | Unusual | SEC |
| Jun 5, 2017 | Samath Jamie | VP & Principal Accounting Offi | Form 4 sale | 1,946 | $1.8M | 100.0% | Unusual | SEC |
| Jun 1, 2017 | Brogna Salvatore | EVP - Product Operations | Form 4 sale | 1,306 | $1.2M | 73.6% | Unusual | SEC |
| May 31, 2017 | Johnson Amal M | Director | Form 4 sale | 1,000 | $917k | 26.4% | Unusual | SEC |